EXEL Exelixis Inc.
21.72
+1.78 (+9%)
Previous Close
19.94
Open
20.01
Price To Book
4.42
Market Cap
6,579,123,489
Shares
302,906,238
Volume
7,428,598
Short Ratio
Av. Daily Volume
2,526,539
NewsSee all news
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Phase 3 data did not meet primary endpoint - June 20, 2019.
IMspire170 - cobimetinib and atezolizumab
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
Phase 3 data released May 10, 2018. Primary endpoint not met.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 2 ongoing.
CABOMETYX (cabozantinib)
Recurrent endometrial cancer
CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER
First-line renal cell carcinoma
Approved November 29, 2012.
Cabozantinib
Medullary thyroid cancer
Phase 3 trial met primary endpoint - September 24, 2017. Japanese regulatory filing due 1Q 2018.
Esaxerenone (CS-3150)
Essential hypertension
Late breaker at ESMO September 10, 2017 showed PFS 8.6 months versus 5.3 months for sunitinib. HR 0.48. PDUFA date under priority review for sNDA February 15, 2018. Approval announced December 19, 2017.
Cabozantinib - CABOSUN
First-Line RCC - cancer
FDA Approval announced January 14, 2019.
Cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
Approved April 25 2016.
CABOMETYX (cabozantinib)
Metastatic renal cell cancer (RCC)
Approved November 10, 2015.
Vemurafenib
BRAF V600 Mutation-Positive Advanced Melanoma - Cancer
Phase 3 COMET-2 trial did not meet endpoint December 1 2014
Cabozantinib
Cancer - Castration-Resistant Prostate Cancer
Phase 3 trial initiation announced October 8, 2018.
Cabozantinib
Thyroid Carcinoma
IMspire150 - cobimetinib, atezolizumab and vemurafenib - TRILOGY
BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma
Phase 1b additional four cohorts added - noted July 15, 2019.
Cabozantinib + atezolizumab (TECENTRIQ) COSMIC-021
Solid tumors
Phase 3 initiation announced December 5, 2018.
CABOMETYX (cabozantinib) + atezolizumab (TECENTRIQ) - (COSMIC-312)
Hepatocellular Carcinoma
Phase 1 trial initiation announced February 12, 2019.
XL092
Solid tumors
Phase 3 trial initiation announced May 1, 2019.
Cabozantinib and Nivolumab and Ipilimumab (COSMIC-313)
Renal Cell Carcinoma
Latest News
- Exelixis Inc (EXEL) President and CEO Michael Morrissey Sold $704,654 of Shares
- Edited Transcript of EXEL earnings conference call or presentation 31-Jul-19 9:00pm GMT
- Exelixis Hits Blockbuster Status
- Is Exelixis, Inc. (NASDAQ:EXEL) A High Quality Stock To Own?
- Exelixis Stock Rises on Revenue Beat
- Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines
- The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings
- Exelixis Inc (EXEL) Q2 2019 Earnings Call Transcript
- Exelixis (EXEL) Q2 Earnings and Revenues Beat Estimates
- Exelixis Announces Second Quarter 2019 Financial Results and Provides Corporate Update
- Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer
- The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster
- Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards?
- 3 Cancer Treatment Stocks to Buy Right Now
- 10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar
- Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
- Can Exelixis (EXEL) Keep the Earnings Surprise Streak Alive?
- Exelixis (NASDAQ:EXEL) Shareholders Have Enjoyed A Whopping 474% Share Price Gain